Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2178-2184

  Bottomley, Andrew ^a   Debruyne, Channa ^a   Felip, Enriqueta ^b   Millward, Michael ^c   Thiberville, Luc ^d   Addario, Giannicola D' ^e   Rome, Lisa ^f   Zatloukal, Petr ^g   Coens, Corneel ^a   Giaccone, Giuseppe ^h  

^a EORTC DATA CENTER   (Belgium)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Digestive Disease Section   (United States)

^g CHARLES UNIVERSITY   (Czech Republic)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Quality of life; Symptom

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BCG VACCINE; BEC2 ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CANCER VACCINES; COMBINED MODALITY THERAPY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PATIENT COMPLIANCE; QUALITY OF LIFE; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; VACCINATION;

EID: 53249153466     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.036     Document Type: Article

References (10)

1. Lally B.E., Urbanic J.J., Blackstock A.W., Miller A.W., and Perry M.C. Small cell lung cancer: have we made any progress over the last 25 years?. Oncologist 12 9 (2007) 1096-1104
2. Giaccone G., Debruyne C., Felip E., et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European organisation for research and treatment of cancer 08971-08971B; silva study). J Clin Oncol 23 28 (2005) 6854-6864
3. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
4. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., and Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life. Eur J Cancer 30A (1994) 635-642
5. Bottomley A., Efficace F., Thomas R., Vanvoorden V., and Ahmedzai S. Health related quality of life in non small cell lung cancer: methodological issues in randomized controlled trials. J Clin Oncol 21 (2003) 2989-2992
6. Cull A., Sprangers M.A.G., Bjordal K., Aaronson N.K., West K., and Bottomley A. Guidelines for translating EORTC questionnaires (2002), Quality of Life Study Group Publications, EORTC Publications, Brussels, Belgium
7. Fayers P., Aaronson N., Bjordal K., Groenvold M., Curran D., and Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. (2001), EORTC Publications, Brussels, Belgium
8. Osoba D., Rodrigues G., Myles J., Zee B., and Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998) 139-144
9. Scott N.W., Fayers P.M., Aaronson N.K., et al. EORTC QLQ-C30 reference values (2008), EORTC Quality of Life Group, EORTC publications
10. Shepherd F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the national cancer institute of Canada-clinical trials group and the European organisation for research and treatment of cancer. J Clin Oncol 20 (2002) 4434-4439